Atara Biotherapeutics Inc  

(Public, NASDAQ:ATRA)   Watch this stock  
Find more results for ATRA
45.40
-1.65 (-3.51%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 43.95 - 49.25
52 week 11.80 - 49.90
Open 46.50
Vol / Avg. 810,307.00/1.17M
Mkt cap 1.39B
P/E     -
Div/yield     -
EPS -3.47
Shares 37.60M
Beta 2.71
Inst. own 93%
Jan 9, 2018
Atara Biotherapeutics Inc at JPMorgan Healthcare Conference
Dec 29, 2017
Atara Biotherapeutics, Inc. - Special Call - Webcast
Nov 29, 2017
Atara Biotherapeutics Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -52.64% -26.85%
Return on average equity -58.41% -27.79%
Employees 96 -
CDP Score - -

Address

611 Gateway Blvd Ste 900
SOUTH SAN FRANCISCO, CA 94080-7015
United States - Map
+1-650-2788930 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Officers and directors

Isaac E. Ciechanover M.D. Chairman of the Board, President, Chief Executive Officer
Age: 46
Bio & Compensation  - Reuters
John F. McGrath Jr. Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Joseph Newell Executive Vice President, Chief Technical Operations Officer
Age: 47
Bio & Compensation  - Reuters
Christopher M. Haqq M.D. Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Heather D. Turner Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy
Age: 43
Bio & Compensation  - Reuters
Mitchall G. Clark Executive Vice President and Chief Regulatory and Quality Assurance Officer
Age: 55
Bio & Compensation  - Reuters
Gad Soffer Executive Vice President and Chief Strategy Officer
Age: 39
Bio & Compensation  - Reuters
Kanya Rajangam M.D. Ph.D. Senior Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Carol G. Gallagher Pharm.D. Lead Independent Director
Age: 52
Bio & Compensation  - Reuters
Eric L. Dobmeier Independent Director
Age: 48
Bio & Compensation  - Reuters